
PARP1 inhibition reduces NAD+ consumption, enhancing SIRT1-mediated activation of antioxidant gene programs. Simultaneously activates AMPK-mediated metabolic reprogramming toward pentose phosphate pathway, increasing NADPH production for alternative antioxidant systems (thioredoxin, peroxiredoxin) to compensate for glutathione deficiency.
IPFS: QmZMFn2toWJvz5DuD15Ef89wEqpVZbvK1QzJQ2LWeVEmjb. TX: 0xe84c8701597a8e94663fc23530faede06302ffa0ef425b462edbe9f06628a885. CC0.
drug repurposing, Glutathione synthetase deficiency, MedicOath, repurposing
drug repurposing, Glutathione synthetase deficiency, MedicOath, repurposing
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
